GE Capital, Healthcare Financial Services announced it is serving as sole lender and administrative agent on $12 million in senior secured credit facilities for SIGA Technologies, Inc., consisting of a $5 million term loan and a $7 million revolving line of credit.

Headquartered in New York City, SIGA specializes in the development and commercialization of pharmaceuticals to prevent and treat some of the most lethal, disease-causing pathogens in the world, including smallpox, Ebola, dengue, Lassa fever and other dangerous viruses.

"GE Capital understands our business and quickly delivered a competitive financing package that meets our needs," said Daniel Luckshire, executive vice president and CFO of SIGA. "In GE Capital, we have a lender who will work closely with us as we continue to grow our business."

"SIGA, like many commercial-stage pharmaceutical companies, has sophisticated needs for continuing access to efficiently-priced capital," said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. "With a team of specialists, we provide pharma companies with a deep level of knowledge and great flexibility in meeting their capital needs."

With in-depth industry knowledge and expertise, GE Capital, Healthcare Financial Services has provided more than $60 billion in financing over ten years to companies in over 45 healthcare sectors including senior housing, hospitals, medical offices, outpatient services, pharmaceuticals and medical devices. Our team of professionals creates business and financial solutions tailored to meet the its customers.